GLT8D1 and glioblastoma: Direct blockade of the GLT8D1/CD133 complex formation through CD133N1-108, or inhibiting GLT8D1 expression through lercanidipine can suppress Wnt/β-catenin-dependent tumorigenesis in vitro and in a xenograft mouse model of GBM patient-derived tumors [40].